Point72 Hong Kong’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $4.48M | Buy |
5,866
+863
| +17% | +$642K | 0.21% | 90 |
|
|
2025
Q2 | $3.9M | Sell |
5,003
-938
| -16% | -$729K | 0.25% | 95 |
|
|
2025
Q1 | $4.91M | Sell |
5,941
-6,064
| -51% | -$5.05M | 0.31% | 72 |
|
|
2024
Q4 | $9.27M | Sell |
12,005
-13,937
| -54% | -$11.5M | 0.57% | 46 |
|
|
2024
Q3 | $23M | Buy |
+25,942
| New | +$23.3M | 1.57% | 10 |
|
|
2024
Q1 | – | Sell |
-12,700
| Closed | -$7.4M | – | 694 |
|
|
2023
Q4 | $7.4M | Buy |
+12,700
| New | +$7.41M | 0.44% | 63 |
|
|
2022
Q3 | – | Sell |
-326
| Closed | -$103K | – | 2189 |
|
|
2022
Q2 | $106K | Sell |
326
-43,102
| -99% | -$12.9M | ﹤0.01% | 1171 |
|
|
2022
Q1 | $12.4M | Buy |
43,428
+28,497
| +191% | +$7.33M | 0.43% | 30 |
|
|
2021
Q4 | $4.12M | Buy |
+14,931
| New | +$3.79M | 0.14% | 146 |
|
|
2021
Q3 | – | Sell |
-16,631
| Closed | -$4.1M | – | 2244 |
|
|
2021
Q2 | $3.82M | Buy |
16,631
+11,254
| +209% | +$2.26M | 0.12% | 188 |
|
|
2021
Q1 | $1M | Sell |
5,377
-1,362
| -20% | -$266K | 0.03% | 658 |
|
|
2020
Q4 | $1.14M | Buy |
+6,739
| New | +$1.01M | 0.05% | 433 |
|
|
2020
Q2 | – | Sell |
-2,093
| Closed | -$290K | – | 1307 |
|
|
2020
Q1 | $290K | Buy |
2,093
+131
| +7% | +$18K | 0.13% | 59 |
|
|
2019
Q4 | $258K | Sell |
1,962
-4,864
| -71% | -$564K | 0.06% | 272 |
|
|
2019
Q3 | $763K | Buy |
6,826
+5,833
| +587% | +$649K | 0.22% | 45 |
|
|
2019
Q2 | $110K | Buy |
993
+134
| +16% | +$15.8K | 0.03% | 471 |
|
|
2019
Q1 | $111K | Buy |
+859
| New | +$104K | 0.04% | 334 |
|
|
2018
Q4 | – | Sell |
-36
| Closed | -$4K | – | 1066 |
|
|
2018
Q3 | $4K | Buy |
+36
| New | +$3.6K | ﹤0.01% | 724 |
|
|
2018
Q1 | – | Sell |
-104
| Closed | -$9K | – | 1040 |
|
|
2017
Q4 | $9K | Buy |
+104
| New | +$8.85K | 0.01% | 508 |
|
|
2017
Q2 | – | Sell |
-1,761
| Closed | -$148K | – | 929 |
|
|
2017
Q1 | $148K | Buy |
1,761
+1,239
| +237% | +$99.2K | 0.19% | 82 |
|
|
2016
Q4 | $38K | Buy |
522
+122
| +31% | +$9.09K | 0.04% | 425 |
|
|
2016
Q3 | $32K | Buy |
+400
| New | +$32K | 0.02% | 526 |
|
|
2016
Q2 | – | Sell |
-1,900
| Closed | -$137K | – | 599 |
|
|
2016
Q1 | $137K | Buy |
1,900
+600
| +46% | +$45.4K | 0.27% | 86 |
|
|
2015
Q4 | $110K | Buy |
+1,300
| New | +$108K | 0.36% | 84 |
|
|
2014
Q4 | – | Sell |
-1,051
| Closed | -$68K | – | 590 |
|
|
2014
Q3 | $68K | Buy |
+1,051
| New | +$66.5K | 0.04% | 183 |
|
Other funds holding LLY
Point72 Hong Kong's LLY Position: Q3 2025 in Review
Point72 Hong Kong increased its Eli Lilly (LLY) stake by 17% in Q3 2025, buying an estimated $642K and bringing the position to 5,866 shares worth $4.48M. The position accounts for 0.21% of the portfolio, ranked #90.
Point72 Hong Kong first reported a position in LLY in Q3 2014 and has held it in 25 quarters since. The position peaked at $23M in Q3 2024. 3,898 funds tracked by Wall St. Rank hold LLY as of Q3 2025.
- Point72 Hong Kong held 5,866 shares of Eli Lilly worth $4.48M as of Q3 2025.
- Point72 Hong Kong bought 863 Eli Lilly shares in Q3 2025, an estimated $642K.
- Eli Lilly made up 0.21% of Point72 Hong Kong's portfolio in Q3 2025, its #90 holding.
- Point72 Hong Kong first reported a position in Eli Lilly in Q3 2014 and has held it in 25 quarters since.
- Point72 Hong Kong's Eli Lilly position peaked at $23M in Q3 2024.
- 3,898 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2025.
Based on Point72 Hong Kong's 13F filing for Q3 2025, filed 14 Nov 2025.